Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | TYMP | P19971 | 4/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.39 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080722 | 1.00 | ADORA1 (0.49) | ADORA1TYMPPRMT5WDR77NT5E | |
| SCHEMBL20305315 | 0.89 | NT5E (0.49) | TYMPNT5E | |
| SCHEMBL20333313 | 0.89 | NT5E (0.49) | TYMPNT5E | |
| SCHEMBL30115178 | 0.89 | NT5E (0.49) | TYMPNT5E | |
| SCHEMBL24191239 | 0.87 | ADORA1 (0.49) | ADORA1TYMPNT5ETRDMT1 | |
| SCHEMBL1068389 | 0.86 | TYMP (0.55) | ADORA1TYMPPRMT5WDR77NT5E | |
| SCHEMBL1068391 | 0.86 | TYMP (0.55) | ADORA1TYMPPRMT5WDR77NT5E | |
| SCHEMBL3796369 | 0.84 | ADORA2B (0.44) | ADORA1TYMP | |
| SCHEMBL12067762 | 0.81 | BCHE (0.49) | ADORA1TYMPPRMT5WDR77NT5E | |
| SCHEMBL28827070 | 0.81 | ADORA1 (0.51) | ADORA1TYMPNT5ETRDMT1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005595-A2 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ADORA1 2126/4885TYMP 250/4885PRMT5 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.